[Management View]
Labcorp reported a 9% increase in revenue to $3.6 billion, driven by diagnostics and central laboratories. Adjusted EPS rose 19%, reflecting margin improvements. The company is focusing on strategic investments in AI and new test offerings, including the first FDA-cleared blood-based Alzheimer’s diagnostic test.

[Outlook]
Labcorp narrowed its full-year 2025 revenue growth guidance to 7.4%-8% and adjusted EPS guidance to $16.16-$16.50, implying 12% growth. The company expects enterprise margins to improve further in both Diagnostics and BLS segments for the full year 2025.

[Financial Performance]
Revenue increased 9% YoY, with Diagnostics segment revenue up 8.5% and BLS segment revenue up 8.3%. Adjusted operating income was $513 million, representing 14.4% of revenue. Free cash flow was $281 million, contributing to a quarter-end cash balance of $598 million.

[Q&A Highlights]
Question 1: Lisa Christine Gill from JPMorgan asked about the impact of currency and acquisitions on revenue guidance and whether increased utilization was observed due to potential changes in benefits.
Answer: Christin O'Donnell explained that $13 million of the impact was from foreign exchange, with the rest from acquisition timing. Utilization increases were attributed to organic volume growth rather than concerns about losing ACA benefits.

Question 2: Michael Cherny of Leerink Partners inquired about the strength of organic price per mix and its proactive versus reactive nature.
Answer: Christin O'Donnell and Julia A. Wang detailed that organic price mix grew 2.8%, driven by increased tests per session and Invitae. Long-term growth is expected from partnerships with hospitals and health systems, as well as demographic trends.

Question 3: Jack Meehan of Nephron Research sought clarification on site consolidation in the early development business and its impact on earnings.
Answer: Christin O'Donnell explained that site consolidation and divestiture of non-core areas would lead to a $50 million reduction in annual revenue but a slight increase in operating income, positively affecting accretion.

[Sentiment Analysis]
Analysts expressed interest in understanding the strategic decisions and their implications. Management maintained a confident tone, emphasizing strong execution and future growth potential.

[Quarterly Comparison]
| Metric | Q3 2025 | Q3 2024 |
|-------------------------------|---------|---------|
| Revenue | $3.6B | $3.3B |
| Adjusted EPS | 19% | 16% |
| Diagnostics Revenue | $2.8B | $2.58B |
| BLS Revenue | $799M | $738M |
| Free Cash Flow | $281M | $260M |

[Risks and Concerns]
Risks include the impact of foreign exchange rates and acquisition timing on revenue growth. The divestiture and consolidation of non-core early development sites may affect revenue but are expected to improve operating income.

[Final Takeaway]
Labcorp's Q3 2025 performance highlights strategic streamlining and investment in AI and new diagnostic offerings as key growth drivers. Despite challenges from foreign exchange and acquisition timing, the company remains focused on delivering sustainable growth and long-term value for shareholders. The introduction of innovative tests and expansion of strategic partnerships position Labcorp as a leader in the diagnostics industry.